Afficher la notice abrégée

Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction

dc.rights.licenseopenen_US
dc.contributor.authorGRIMALDI-BENSOUDA, L.
dc.contributor.authorDANCHIN, N.
dc.contributor.authorDALLONGEVILLE, J.
dc.contributor.authorFALISSARD, B.
dc.contributor.authorFURBER, A.
dc.contributor.authorCOTTIN, Y.
dc.contributor.authorBONELLO, L.
dc.contributor.authorMOREL, O.
dc.contributor.authorLECLERCQ, F.
dc.contributor.authorPUYMIRAT, E.
dc.contributor.authorGHANEM, F.
dc.contributor.authorDELARCHE, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBENICHOU, Jacques
dc.contributor.authorABENHAIM, L.
dc.date.accessioned2020-11-10T15:29:12Z
dc.date.available2020-11-10T15:29:12Z
dc.date.issued2018-10
dc.identifier.issn1355-6037en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/12217
dc.description.abstractEnOBJECTIVE: To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions. METHODS: Case-referent study using the Pharmacoepidemiological General Research eXtension (PGRx)-acute coronary syndrome (ACS) registry. Cases were patients with reMI from a cohort with index ACS or external to the cohort (same sites). Referents from the cohort, without recurrent event, were matched on index ACS type and date, age and sex with reMI cases. Multivariate conditional logistic regression assessed the OR (95% CI) for reMI associated with ticagrelor and prasugrel vs clopidogrel, adjusted for aspirin use and cardiovascular risk factors. RESULTS: 1047 cases and 2234 matched referents were included. Compared with clopidogrel, ticagrelor and prasugrel were associated with respective ORs of 0.65 (95% CI 0.52 to 0.81) and 0.71 (95% CI 0.53 to 0.96) for reMI occurrence. ORs for ticagrelor and prasugrel vs clopidogrel were: 0.50 (95% CI 0.38 to 0.67) and 0.66 (95% CI 0.45 to 0.95), 0.39 (95% CI 0.24 to 0.62) and 0.44 (95% CI 0.26 to 0.75), 0.63 (95% CI 0.43 to 0.92) and 1.20 (95% CI 0.69 to 2.07), 1.11 (95% CI 0.72 to 1.72) and 0.82 (95% CI 0.44 to 1.54) when index ACS was a first MI, a first ST-elevated MI (STEMI), a first non-STEMI and a recurrent ACS, respectively, and 0.63 (95% CI 0.45 to 0.87) and 0.77 (95% CI 0.41 to 1.45) for patients aged >/=70 years. CONCLUSIONS: This real-world study showed a significant reduction of reMI with new antiplatelets compared with clopidogrel, ticagrelor being associated with a greater decrease of risk notably for first, either STEMI or non-STEMI. The larger magnitude of effect may be attributed to potential residual confounding or higher effectiveness compared with efficacy reported in trials (EMA Post Authorisation Study Registry Number EUPAS5905).
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enEffectiveness of new antiplatelets in the prevention of recurrent myocardial infarction
dc.title.alternativeHearten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/heartjnl-2017-312534en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29535227en_US
bordeaux.journalHeart (British Cardiac Society)en_US
bordeaux.page1583-1592en_US
bordeaux.volume104en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue19en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.date=2018-10&rft.volume=104&rft.issue=19&rft.spage=1583-1592&rft.epage=1583-1592&rft.eissn=1355-6037&rft.issn=1355-6037&rft.au=GRIMALDI-BENSOUDA,%20L.&DANCHIN,%20N.&DALLONGEVILLE,%20J.&FALISSARD,%20B.&FURBER,%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée